ERAL1 and breast cancer: Transcriptional analysis of the impact of 4-OHT has been widely performed in MCF7 or in tamoxifen-resistant breast cancers 48, 49 since tamoxifen remains an important drug in the adjuvant and metastasis setting of ERα-positive tumors.